Compare Thomson Reuters Corp (TRI) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Thomson Reuters Corp vs DENTSPLY SIRONA Inc — how do they compare? Thomson Reuters Corp trades at $101.71 (market cap $43.89B), while DENTSPLY SIRONA Inc trades at $8.73 (market cap $1.73B). The key difference: Thomson Reuters Corp is far larger — about 25.4× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals — on Pluang, investors hold Thomson Reuters Corp for 63 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| TRI | XRAY | |
|---|---|---|
Market Cap | $43.89B | $1.73B |
Volume | 1,648,199 | 6,198,582 |
Sector | Industrials | Health |
52-Week High | $163.45 | $14.68 |
52-Week Low | $76.55 | $8.52 |
Typical Hold Time | 63 Days | 72 Days |
Enterprise Value | $46.51B | $3.80B |
Dividend Yield | 2.58% | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Thomson Reuters (TRI) trades at $101.71, up 2.45% today, with a bullish technical outlook and strong analyst consensus. The stock shows robust fundamentals with a 21.22% net income margin and 10% organic growth in core businesses. Recent strategic moves include divesting its print unit to focus on technology and launching a proprietary AI model, positioning for future growth.
The outlook is positive with a consensus price target of $133.25, implying significant upside. Key risks include execution of the AI strategy and cybersecurity concerns. Institutional buying and insider purchases support confidence, but investors should monitor earnings performance and competitive pressures in the legal tech space.
Dentsply Sirona (XRAY) trades at $8.73, near its 52-week low, with a bearish technical signal and negative profitability metrics. The company reported a Q2 2026 earnings beat but faces declining revenue and negative net income margins. Recent news highlights institutional stake increases and ongoing restructuring efforts amid a challenging dental market environment.
The outlook remains cautious due to persistent margin pressure and sales declines, though the consensus price target of $13.40 suggests potential upside. Key risks include competitive pressures and execution of the turnaround plan, while institutional buying indicates some long-term confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
